|
bone destruction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, the TNF-α-induced CD80 may augment CTLA-4-Ig-induced inhibition of osteoclastogenesis, suggesting that CTLA-4-Ig potently inhibits osteoclast differentiation and protects bone destruction in rheumatoid inflamed joints.
|
30724348 |
2019 |
|
bone destruction
|
0.100 |
Biomarker
|
disease |
BEFREE |
The osteoclast differentiation factor receptor activator of NF-κB ligand (RANKL), which belongs to the tumor necrosis factor superfamily, plays a critical role in osteoclast differentiation and bone destruction in RA.
|
28880683 |
2018 |
|
bone destruction
|
0.100 |
Biomarker
|
disease |
BEFREE |
<i>In vitro</i>, TNFα could induce RAW264.7 cells to differentiate into mature osteoclasts, leading to bone destruction.
|
29980532 |
2018 |
|
bone destruction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Receptor activator of NF-κB ligand (RANKL), which belongs to the tumor necrosis factor superfamily, is indispensable for osteoclast differentiation and bone destruction in RA.
|
30075997 |
2018 |
|
bone destruction
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, IL-23 affects the pathogenesis of inflammation and bone destruction through interaction with other cytokines such as IL-17 and TNF-α.
|
28850053 |
2017 |
|
bone destruction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cytokines released from macrophages such as TNF-α, IL-1β and IL-6 the main players that precede cartilage and bone destruction during septic arthritis (SA) followed by osteoclast differentiation and bone resorption.
|
29074430 |
2017 |
|
bone destruction
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
TNF-α serum levels correlated negatively with Def6 expression levels in osteoclast precursors obtained from RA patients, and the osteoclastogenic capacity of the osteoclast precursors was significantly inversely correlated with their Def6 expression levels, indicating that Def6 functions as an inhibitor of excessive osteoclast formation and bone destruction in RA.
|
28314855 |
2017 |
|
bone destruction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor (TNF) drives bone destruction, but it also inhibits new bone formation by inducing Dkk-1, an inhibitor of the Wnt pathway.
|
25941031 |
2015 |
|
bone destruction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Loss of SH3 domain-binding protein 2 function suppresses bone destruction in tumor necrosis factor-driven and collagen-induced arthritis in mice.
|
25470448 |
2015 |
|
bone destruction
|
0.100 |
Biomarker
|
disease |
BEFREE |
We identified a critical role of tumor necrosis factor α (TNF-α) in the development of autoinflammation by creating homozygous TNF-α-deficient cherubism mutants, in which systemic inflammation and bone destruction were rescued.
|
24978678 |
2014 |
|
bone destruction
|
0.100 |
Biomarker
|
disease |
BEFREE |
TNF-α is expressed in human cherubism lesions, which contain a large number of tartrate-resistant acid phosphatase (TRAP)-positive multinucleated cells, and TNF-α plays a critical role in inflammatory bone destruction in homozygous cherubism mice (Sh3bp2(KI/KI) ).
|
24916406 |
2014 |
|
bone destruction
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To investigate the expression of TNF-α, IFN-γ, TGF-β, and IL-4 in the spinal tuberculous focus and its relationship with the lesions type, severity, and bone destruction.
|
25326857 |
2014 |
|
bone destruction
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, the effects of TNF inhibition on osteoclast precursors as well as local bone destruction in vivo were assessed by treating TNF-transgenic mice with different doses of adalimumab.
|
23280418 |
2013 |
|
bone destruction
|
0.100 |
Biomarker
|
disease |
BEFREE |
The inhibition of TNF-α may thus provide a new therapeutic approach to control tumour progression and bone destruction in MM patients.
|
23932230 |
2013 |
|
bone destruction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Wnt inhibitory factor 1 deficiency uncouples cartilage and bone destruction in tumor necrosis factor α-mediated experimental arthritis.
|
23784913 |
2013 |
|
bone destruction
|
0.100 |
Biomarker
|
disease |
BEFREE |
In TNF-mediated bone destruction, bortezomib treatment increased synovial osteoclastogenesis and bone destruction.
|
21360496 |
2011 |
|
bone destruction
|
0.100 |
Biomarker
|
disease |
BEFREE |
TNF and RANKL mediate bone destruction in common bone diseases, including osteoarthritis and RA.
|
19770515 |
2009 |
|
bone destruction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cathepsin K deficiency partially inhibits, but does not prevent, bone destruction in human tumor necrosis factor-transgenic mice.
|
18240253 |
2008 |
|
bone destruction
|
0.100 |
Biomarker
|
disease |
BEFREE |
We previously reported that administration of an adeno-associated virus 2 (AAV2) vector encoding a rat tumor necrosis factor (TNF) receptor-immunoglobulin Fc (TNFR:Fc) fusion gene to rats with streptococcal cell wall-induced arthritis resulted in suppression of joint inflammation and cartilage and bone destruction, as well as expression of joint proinflammatory cytokines.
|
17235303 |
2007 |
|
bone destruction
|
0.100 |
Biomarker
|
disease |
BEFREE |
Specifically, OSM + TNFalpha induced marked synovial hyperplasia, inflammation, and cartilage and bone destruction with a concomitant increase in MMP expression in both cartilage and synovium and decreased TIMP-1 expression in the articular cartilage.
|
14673992 |
2003 |
|
bone destruction
|
0.100 |
Biomarker
|
disease |
BEFREE |
To study the effects of osteoclast-targeted therapies, such as osteoprotegerin (OPG) and pamidronate, on joint inflammation and bone destruction using a tumor necrosis factor alpha (TNF alpha)-transgenic mouse model.
|
11920416 |
2002 |
|
bone destruction
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, despite the presence of severe inflammatory changes, c-fos(-/-)hTNFtg mice were fully protected against bone destruction.
|
12438440 |
2002 |